古塞奇尤单抗治疗斑块状银屑病伴湿疹患者1例
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i3.14476
Abstract
老年男性斑块状银屑病患者,给予司库奇尤单抗治疗30周后,患者出现湿疹样皮损及药效减弱,严重影响患者生活,更换生物制剂予古塞奇尤单抗治疗,第一针注射3天后,双手、双足及双下肢出现红斑、脓疱,一周后皮疹消退,肿胀消失。继续治疗30周后银屑病皮损得到控制且无不良反应发生。
Keywords
斑块状银屑病；古塞奇尤单抗；司库奇尤单抗
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 张学军.中国银屑病诊疗指南(2018完整版)[J].中华皮肤科杂志,2019,52(10):667-695,696.
[2] Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17treatment of psoriasis: an emerging condition[J].Br J Dermatol,2019,181:604-606.
[3] Munera-Campos M,Ballesca F,Richarz N,et al.Paradoxic al eczematous reaction to ixekizumab[J].J Eur Acad Dermatol Venereol,2019,33:e40-e42.
[4] Tang H et al.A large-scale screen for coding variants predisposing to psoriasis.Nat Genet. 2014Jan;46(1):45-50.
[5] Gordon KB,Armstrong AW,Foley P,et al.Guselkumab effic acy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study [J].J Invest Dermatol,2019,139(12):2437-2446.e1.
[6] Harper EG,Guo C,Rizzo H,et al.Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-83.
[7] Griffiths CEM,Armstrong AW,Gudjonsson JE,Barker JNWN. Psoriasis.Lancet.2021 Apr 3;397(10281):1301-1315.
[8] Xing X,Liang Y, Sarkar MK, et al.IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis. J Invest Dermatol 2016;136: 2498-501.
[9] Nestle FO,Conrad C,Tun-Kyi A,et al.Plasmacytoid prede ndritic cells initiate psoriasis through interferon-alpha pr oduction.J Exp Med 2005;202:135-43.
[10] Sano S,Kubo H,Morishima H,et al.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients wi th generalized pustular psoriasis and erythrodermic psoriasis:efficacy and safety analyses of a 52-week, phase 3,multicent er,open-label study[J].J Dermatol,2018,45(5):529-539.
[2] Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17treatment of psoriasis: an emerging condition[J].Br J Dermatol,2019,181:604-606.
[3] Munera-Campos M,Ballesca F,Richarz N,et al.Paradoxic al eczematous reaction to ixekizumab[J].J Eur Acad Dermatol Venereol,2019,33:e40-e42.
[4] Tang H et al.A large-scale screen for coding variants predisposing to psoriasis.Nat Genet. 2014Jan;46(1):45-50.
[5] Gordon KB,Armstrong AW,Foley P,et al.Guselkumab effic acy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study [J].J Invest Dermatol,2019,139(12):2437-2446.e1.
[6] Harper EG,Guo C,Rizzo H,et al.Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-83.
[7] Griffiths CEM,Armstrong AW,Gudjonsson JE,Barker JNWN. Psoriasis.Lancet.2021 Apr 3;397(10281):1301-1315.
[8] Xing X,Liang Y, Sarkar MK, et al.IL-17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis. J Invest Dermatol 2016;136: 2498-501.
[9] Nestle FO,Conrad C,Tun-Kyi A,et al.Plasmacytoid prede ndritic cells initiate psoriasis through interferon-alpha pr oduction.J Exp Med 2005;202:135-43.
[10] Sano S,Kubo H,Morishima H,et al.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients wi th generalized pustular psoriasis and erythrodermic psoriasis:efficacy and safety analyses of a 52-week, phase 3,multicent er,open-label study[J].J Dermatol,2018,45(5):529-539.
Copyright © 2025 赵卉, 张楠
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License